Takeya Sugimoto

Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.

Toshiaki Takahashi, H. Akamatsu, H. Daga, 2019, Japanese journal of clinical oncology.

Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation

Y. Koh, N. Yamamoto, Y. Ozawa, 2021, Anticancer Research.

Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study

M. Kokubo, J. Uchida, Y. Fukuda, 2021, Investigational New Drugs.